ETM
UTHR icon

Euclidean Technologies Management’s United Therapeutics UTHR Stock Holding History

Euclidean Technologies Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,270
Closed -$212K – 104
2021
Q1 		$212K Buy
+1,270
New +$212K 0.18% 61

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Euclidean Technologies Management's UTHR Position: Q2 2021 in Review

Euclidean Technologies Management sold out of United Therapeutics (UTHR) in Q2 2021, closing a stake of 1,270 shares — an estimated $212K sold.

Euclidean Technologies Management first reported a position in UTHR in Q1 2021 and held it in 1 quarter. The position peaked at $212K in Q1 2021. 402 funds tracked by Wall St. Rank hold UTHR as of Q2 2021.

  • Euclidean Technologies Management reported no remaining United Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Euclidean Technologies Management sold 1,270 United Therapeutics shares in Q2 2021, an estimated $212K.
  • Euclidean Technologies Management first reported a position in United Therapeutics in Q1 2021 and held it in 1 quarter.
  • Euclidean Technologies Management's United Therapeutics position peaked at $212K in Q1 2021.
  • 402 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2021.

Based on Euclidean Technologies Management's 13F filing for Q2 2021, filed 5 Aug 2021.